Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
Status:
Recruiting
Trial end date:
2023-12-07
Target enrollment:
Participant gender:
Summary
The CaPture trial is a prospective, multi-centre, non-randomized phase II study. Its aim is
to assess feasibility, safety and efficacy signals of Cabozantinib treatment in patients with
HCC and prior non-response or disease progression during a PD-1 or PD-L1 inhibitor treatment.
Since the potential study population is very small, the sample size has been fixed in advance
to N = 40. Time on treatment (TT) will be measured as primary endpoint.